Skip to main content
. 2021 Jan 6;26(6):e996–e1008. doi: 10.1002/onco.13643

Figure 4.

Figure 4

Multivariable analysis of overall survival in the post‐MTB versus pre‐MTB implementation periods within each subgroup of patients with early breast cancer (stage 0–III). All models included the following variables: MTB implementation period (pre vs. post), age (<40 vs. 40–49 vs. 50–59 vs. ≥60 years), HIV status (negative/unknown vs. positive), stage at diagnosis (0–II vs. III), and tumor subtype (ER+/HER2− vs. HER2+ vs. TNBC vs. unknown). ¥Among patients receiving any type of breast surgery. Not done/incomplete: 0–5 isolated lymph nodes (in case of axillary lymph node dissection); complete: ≥6 isolated lymph nodes (in case of axillary lymph node dissection) or ≥ 1 isolated lymph nodes with ≤2 positive lymph nodes (in case of sentinel lymph node biopsy). §First‐line of chemotherapy that the patient received includes neoadjuvant and/or adjuvant treatment. If the patient received part of chemotherapy as neoadjuvant (e.g., doxorubicin plus cyclophosphamide [AC] regimen) and another part as adjuvant chemotherapy (e.g., paclitaxel), the type of regimen and dose‐intensity refer to the entire scheme (neoadjuvant plus adjuvant). Abbreviations: CI, confidence interval; CT, chemotherapy; ER, estrogen receptor; ET, endocrine therapy; HR, hazard ratio; MTB, multidisciplinary tumor board; TNBC, triple‐negative breast cancer.